Ildong wins latest round on ofloxacin ear drop

Published: 2004-07-12 06:56:00

Updated: 2004-07-12 06:56:00

Ildong Pharm says that the patent dispute touched off by Daiichi Pharm of Japan fiver years ago against ofloxacin ear drop was substantially terminated by the recent ruling of the Supreme Court and that it may be able to market the antimicrobial agent in the domestic market.

In its ruling, the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK